EUCTR2016-001046-26-Outside-EU/EEA进行中（未招募）1 期
Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents with Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Pediatric patients aged 2-17 years of age;
- •- Histologically confirmed solid tumors;
- •- Cancer which has relapsed after, or failed to respond to, curative therapy, or no other potentially curative treatment options available.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 58
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Treatment with corticosteroids within past 2 weeks;
- •- Current or past use of anti-IGF-1R antibodies;
- •- Current treatment with immunosuppressive agents;
- •- Patients with diabetes mellitus;
- •- Known HIV or hepatitis B or C;
- •- Hypersensitivity to any of the components of R1507 or to monoclonal antibodies.
研究者
相似试验
招募中
不适用
A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients with Advanced Solid Cancersgeavanceerde en/of gemetastaseerde solide tumorensolid tumorscancerNL-OMON38050Roche Nederland B.V.20
招募中
1 期
A Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of SZN-043, a Novel Bispecific Fusion Protein Targeting ASGR1 and ZNRF3/RNF43, in Healthy Volunteers and Subjects with Liver CirrhosisAlcoholic HepatitisInflammatory and Immune System - Other inflammatory or immune system disordersLiver CirrhosisACTRN12622000392763Surrozen Operating, Inc.40
已完成
1 期
A Phase I Multiple Ascending Dose Study of EMA401 Sodium Salt Administered Orally in Healthy Elderly SubjectsPostherpetic NeuralgiaACTRN12610000620022Spinifex Pharmaceuticals Pty Ltd32
撤回
不适用
A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral SclerosisAmyotrophic lateral sclerosisneurodegenerative disease10029317NL-OMON46750Biogen3
已完成
不适用
A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral SclerosisNL-OMON55647Biogen3